Psychedelic Therapies: Safety and Legality of Psychedelic Compounds

Download PDF

When proper doses of psychedelics are taken, most describe their experiences as “out of body” with a new stream of consciousness. This may be key in the treatment of various psychiatric conditions.
  1. Johnson MW, Hendricks PS, Barrett FS, Griffiths RR. Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function. Pharmacol & Ther. 2019 May;197:83-102. Elsevier BV; 2019 May. DOI: 10.1016/j.pharmthera.2018.11.010.
  2. Domínguez-Clavé E, Soler J, Elices M, Pascual JC, Álvarez E, de la Fuente Revenga M, et al. Ayahuasca: Pharmacology, neuroscience and therapeutic potential. Brain Res Bulletin. 2016 Sep;126:89-101. Elsevier BV; 2016 Sep. DOI: 10.1016/j.brainresbull.2016.03.002.
  3. Palhano-Fontes F, Barreto D, Onias H, Andrade KC, Novaes MM, Pessoa JA, et al. Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial. Psychol Med. 2019 Mar;49(4):655-663. Cambridge University Press (CUP); 2019 Mar. DOI: 10.1017/s0033291718001356.
  4. SAMHSA Fact Sheet. PsycEXTRA Dataset. 2002. Unmaintained records; 2002. DOI: 10.1037/e326522004-001.
  5. Uthaug MV, Davis AK, Haas TF, Davis D, Dolan SB, Lancelotta R, et al. The epidemiology of mescaline use: Pattern of use, motivations for consumption, and perceived consequences, benefits, and acute and enduring subjective effects. J Psychopharmacol. 2022 Mar;36(3):309-320. SAGE Publications; 2022 Mar. DOI: 10.1177/02698811211013583.
  6. Lowe H, Toyang N, Steele B, Valentine H, Grant J, Ali A, et al. The Therapeutic Potential of Psilocybin. Molecules. 2021 May 15;26(10):2948. MDPI AG; 2021 May 15. DOI: 10.3390/molecules26102948.
  7. Richert L, Dyck E. Psychedelic crossings: American mental health and LSD in the 1970s. Med Humanit. 2020 Sep;46(3):184-191. BMJ; 2020 Sep. DOI: 10.1136/medhum-2018-011593.
  8. Varker T, Watson L, Gibson K, Forbes D, O’Donnell ML. Efficacy of Psychoactive Drugs for the Treatment of Posttraumatic Stress Disorder: A Systematic Review of MDMA, Ketamine, LSD and Psilocybin. J Psychoact Drugs. 2021 Jan;53(1):85-95. Informa UK Limited; 2021 Jan. DOI: 10.1080/02791072.2020.1817639.
  9. Passie T, Benzenhöfer U. MDA, MDMA, and other “mescaline‐like” substances in the US military's search for a truth drug (1940s to 1960s). Drug Test Analysis. 2018 Jan;10(1):72-80. Wiley; 2018 Jan. DOI: 10.1002/dta.2292.
  10. Figurasin R, Maguire NJ. 3,4-Methylenedioxy-Methamphetamine Toxicity. StatPearls. 2023. 2023.
  11. Psychedelic Drugs: Considerations for Clinical Investigations Guidance for Industry. 2023. 2023.
  12. Hamill J, Hallak J, Dursun SM, Baker G. Ayahuasca: Psychological and Physiologic Effects, Pharmacology and Potential Uses in Addiction and Mental Illness. CN. 2019 Jan 7;17(2):108-128. Bentham Science Publishers Ltd.; 2019 Jan 7. DOI: 10.2174/1570159x16666180125095902.
  13. Sanches RF, de Lima Osório F, dos Santos RG, Macedo LRH, Maia-de-Oliveira JP, Wichert-Ana L, et al. Antidepressant Effects of a Single Dose of Ayahuasca in Patients With Recurrent Depression. J Clin Psychopharmacol. 2016 Feb;36(1):77-81. Ovid Technologies (Wolters Kluwer Health); 2016 Feb. DOI: 10.1097/jcp.0000000000000436.
  14. PATTERSON AM. Coining Common Names. Chem Eng News Archive. 1955 Nov 7;33(45):4805. American Chemical Society (ACS); 1955 Nov 7. DOI: 10.1021/cen-v033n045.p4805.
  15. Kwan AC, Olson DE, Preller KH, Roth BL. The neural basis of psychedelic action. Nat Neurosci. 2022 Nov;25(11):1407-1419. Springer Science and Business Media LLC; 2022 Nov. DOI: 10.1038/s41593-022-01177-4.
  16. Dinis-Oliveira RJ, Pereira CL, da Silva DD. Pharmacokinetic and Pharmacodynamic Aspects of Peyote and Mescaline: Clinical and Forensic Repercussions. CMP. 2019 Jul 29;12(3):184-194. Elsevier BV; 2019 Jul 29. DOI: 10.2174/1874467211666181010154139.
  17. Husain MI, Blumberger DM, Castle DJ, Ledwos N, Fellows E, Jones BDM, et al. Psilocybin for treatment-resistant depression without psychedelic effects: study protocol for a 4-week, double-blind, proof-of-concept randomised controlled trial. BJPsych open. 2023 Jul;9(4). Royal College of Psychiatrists; 2023 Jul. DOI: 10.1192/bjo.2023.535.
  18. Carhart-Harris RL, Bolstridge M, Rucker J, Day CMJ, Erritzoe D, Kaelen M, et al. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry. 2016 Jul;3(7):619-627. Elsevier BV; 2016 Jul. DOI: 10.1016/s2215-0366(16)30065-7.
  19. Carhart-Harris RL, Bolstridge M, Day CMJ, Rucker J, Watts R, Erritzoe DE, et al. Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology. 2018 Feb;235(2):399-408. Springer Science and Business Media LLC; 2018 Feb. DOI: 10.1007/s00213-017-4771-x.
  20. Ching THW, Grazioplene R, Bohner C, Kichuk SA, DePalmer G, D’Amico E, et al. Safety, tolerability, and clinical and neural effects of single-dose psilocybin in obsessive–compulsive disorder: protocol for a randomized, double-blind, placebo-controlled, non-crossover trial. Front Psychiatry. 2023 Apr 25;14. Frontiers Media SA; 2023 Apr 25. DOI: 10.3389/fpsyt.2023.1178529.
  21. Johnson MW, Garcia-Romeu A, Cosimano MP, Griffiths RR. Pilot study of the 5-HT 2A R agonist psilocybin in the treatment of tobacco addiction. J Psychopharmacol. 2014 Nov;28(11):983-992. SAGE Publications; 2014 Nov. DOI: 10.1177/0269881114548296.
  22. Johnson MW, Garcia-Romeu A, Griffiths RR. Long-term follow-up of psilocybin-facilitated smoking cessation. Am J Drug Alcohol Abus. 2017 Jan 2;43(1):55-60. Informa UK Limited; 2017 Jan 2. DOI: 10.3109/00952990.2016.1170135.
  23. Bogenschutz MP, Forcehimes AA, Pommy JA, Wilcox CE, Barbosa P, Strassman RJ. Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study. J Psychopharmacol. 2015 Mar;29(3):289-299. SAGE Publications; 2015 Mar. DOI: 10.1177/0269881114565144.
  24. Reiff CM, Richman EE, Nemeroff CB, Carpenter LL, Widge AS, Rodriguez CI, et al. Psychedelics and Psychedelic-Assisted Psychotherapy. AJP. 2020 May 1;177(5):391-410. American Psychiatric Association Publishing; 2020 May 1. DOI: 10.1176/appi.ajp.2019.19010035.
  25. Krebs TS, Johansen PØ. Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials. J Psychopharmacol. 2012 Jul;26(7):994-1002. SAGE Publications; 2012 Jul. DOI: 10.1177/0269881112439253.
  26. Agin-Liebes G, Nielson EM, Zingman M, Kim K, Haas A, Owens LT, et al. Reports of self-compassion and affect regulation in psilocybin-assisted therapy for alcohol use disorder: An interpretive phenomenological analysis.. Psychology Addict Behav. 2024 Feb;38(1):101-113. American Psychological Association (APA); 2024 Feb. DOI: 10.1037/adb0000935.
  27. Traynor JM, Roberts DE, Ross S, Zeifman R, Choi-Kain L. MDMA-Assisted Psychotherapy for Borderline Personality Disorder. FOC. 2022 Oct;20(4):358-367. American Psychiatric Association Publishing; 2022 Oct. DOI: 10.1176/appi.focus.20220056.
  28. Mitchell JM, Bogenschutz M, Lilienstein A, Harrison C, Kleiman S, Parker-Guilbert K, et al. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nat Med. 2021 Jun;27(6):1025-1033. Springer Science and Business Media LLC; 2021 Jun. DOI: 10.1038/s41591-021-01336-3.
  29. Lear MK, Smith SM, Pilecki B, Stauffer CS, Luoma JB. Social anxiety and MDMA-assisted therapy investigation: a novel clinical trial protocol. Front Psychiatry. 2023 Jul 14;14. Frontiers Media SA; 2023 Jul 14. DOI: 10.3389/fpsyt.2023.1083354.
  30. Mitchell JM, Ot’alora G. M, van der Kolk B, Shannon S, Bogenschutz M, Gelfand Y, et al. MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial. Nat Med. 2023 Oct;29(10):2473-2480. Springer Science and Business Media LLC; 2023 Oct. DOI: 10.1038/s41591-023-02565-4.
  31. Rudnick G, Wall SC. The molecular mechanism of "ecstasy" [3,4-methylenedioxy-methamphetamine (MDMA)]: serotonin transporters are targets for MDMA-induced serotonin release.. Proc Natl Acad Sci USA. 1992 Mar;89(5):1817-1821. Proceedings of the National Academy of Sciences; 1992 Mar. DOI: 10.1073/pnas.89.5.1817.
  32. van Dijken GD, Blom RE, Hene RJ, Boer WH. High incidence of mild hyponatraemia in females using ecstasy at a rave party. Nephrol Dialysis Transpl. 2013 Sep 1;28(9):2277-2283. Oxford University Press (OUP); 2013 Sep 1. DOI: 10.1093/ndt/gft023.
  33. Johnson M, Richards W, Griffiths R. Human hallucinogen research: guidelines for safety. J Psychopharmacol. 2008 Aug;22(6):603-620. SAGE Publications; 2008 Aug. DOI: 10.1177/0269881108093587.
  34. Schlag AK, Aday J, Salam I, Neill JC, Nutt DJ. Adverse effects of psychedelics: From anecdotes and misinformation to systematic science. J Psychopharmacol. 2022 Mar;36(3):258-272. SAGE Publications; 2022 Mar. DOI: 10.1177/02698811211069100.
  35. Johansen PØ, Krebs TS. Psychedelics not linked to mental health problems or suicidal behavior: A population study. J Psychopharmacol. 2015 Mar;29(3):270-279. SAGE Publications; 2015 Mar. DOI: 10.1177/0269881114568039.